Abstracts tagged "risk factors"

Abstract Number: 2087 • ACR Convergence 2025
Does Carbamazepine Impact Risk of Developing Osteoarthritis? Results of a Real-World Data Analysis
Erfan Afshar¹ and Andrew Long², ¹VCUSOM, Richmond, VA, ²Virginia Commonwealth University Health System, Midlothian, VA
Background/Purpose: Carbamazepine has shown chondroprotective effects in OA animal models by modulating Nav1.7 channels. This study aimed to examine the association between Carbamazepine use and…
Abstract Number: 1579 • ACR Convergence 2025
Exploring the Pulmonary Vascular Changes on Computed Tomography in predicting progression and mortality of Systemic Sclerosis-associated Interstitial Lung Disease
Maria Iacovantuono¹, Nicholas landini², lisa Jungblut³, Florian Käs⁴, Rucsandra Dobrota⁵, Sinziana Muraru⁶, Carina Mihai⁷, Muriel Elhai⁸, Mike Becker⁹, Maria Sole Chimenti¹⁰, Thomas Frauenfelder³, Anna-Maria Hoffmann-Vold¹¹, Oliver Distler¹² and Cosimo Bruni¹³, ¹Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Spinete, Italy, ²Department of Radiological Sciences, Oncology and Pathology, "Sapienza" University, Policlinico Umberto I, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Rueil Malmaison, France, ³Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, zurich, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁶University of Zurich, University Hospital Zurich, Zürich, Switzerland, ⁷University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, Schlieren, Switzerland, ⁹Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, ¹⁰Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy, Roma, Italy, ¹¹Oslo University Hospital, Oslo, Norway, ¹²Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ¹³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is the main cause of mortality in systemic sclerosis (SSc). Among radiomics features, the automated quantification of pulmonary vascular volume…
Abstract Number: 0714 • ACR Convergence 2025
Factors Associated With Depression And Anxiety In ANCA-Associated Vasculitis Patients: Data From The Almenara Vasculitis Cohort
Alvaro Oyarce-Calderón¹, Allison Figueroa-Sánchez², Leonor León-Yaurimucha², Rocío Gamboa-Cárdenas³, Zoila Rodríguez-Bellido⁴, Risto Perich-Campos⁵, Graciela Alarcón⁶, Manuel Ugarte-Gil⁷ and Victor Pimentel-Quiroz⁸, ¹Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Científica del Sur, Lima, Peru, ⁴Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁶The University of Alabama at Birmingham, Oakland, CA, ⁷Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ⁸Universidad Científica del Sur, San Isidro, Peru
Background/Purpose: Depression and anxiety symptoms have been reported in 28% of patients suffering from vasculitides. However, in patients with ANCA-associated vasculitis (AAV), their frequency and…
Abstract Number: 0454 • ACR Convergence 2025
Models to predict flare and sustained remission in Rheumatoid Arthritis patients on optimization treatment with bDMARDs: clinical and molecular insights
Laura Galindo Domínguez¹, Belen Acasuso¹, Vanesa Balboa², Juan Cañete³, Benjamin Fernández-Gutiérrez⁴, Isidoro Gonzalez-Alvaro⁵, jose Luis Pablos⁶, Carmen Bejerano-Herreria⁷, Maite silva⁸, Ignacio rego Pérez⁹, Cristina Ruiz-Romero¹⁰, Francisco J De-Toro-Santos¹¹, Natividad Oreiro¹² and francisco J Blanco¹³, ¹Grupo de Investigación en Reumatología (GIR). INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC). SERGAS, A Coruña, Galicia, Spain, ²Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, coruña, Spain, ³Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ⁴Department of Rheumatology and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Madrid, Spain., Madrid, Madrid, Spain, ⁵Department of Rheumatology, Hospital Universitario La Princesa, IIS, Madrid Spain, Madrid, Spain, ⁶Department of Rheumatology, Instituto de Investigación Hospital ¹² de Octubre, Complutense University of Madrid, Madrid, Madrid, Spain, ⁷Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁸Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain, A Coruña, Galicia, Spain, ⁹Department of Rheumatology, Rheumatology Research Group (GIR) Biomedical Re-search Institute (INIBIC), A Coruña, Spain, ¹⁰Department of Rheumatology, Rheumatology Research Group (GIR) Biomedical Re-search Institute (INIBIC),, A Coruña, Spain, ¹¹Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain, A Coruña, ¹²CHUAC, La Coruna, Spain, ¹³INIBIC-University of A Coruña, A Coruña, Galicia, Spain
Background/Purpose: Optimization of biologic DMARDs (bDMARDs) in patients with rheumatoid arthritis (RA) may be feasible in those who have maintained remission for at least six…
Abstract Number: 2667 • ACR Convergence 2025
Amyloidosis Secondary to Familial Mediterranean Fever: Machine Learning Based Prediction Models
Berkay Aktas¹, Enes Azman¹, Yusuf Ecren Oner², kadir Kaya², husnu Mert Yuksel³, Ali Hosgel², Dilan Karahan², Zehra Beyza Coban², Kerem parlar⁴, Ozgur Can Kilinc¹, Beste Acar¹ and serdal Ugurlu⁵, ¹Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Istanbul, Turkey, ⁴Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, İstanbul, Turkey, ⁵Istanbul University-Cerrahpasa, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Familial Mediterranean Fever (FMF) is a monogenic autoinflammatory disease caused by MEFV mutations. Amyloidosis remains its most serious complication, with several risk factors reported…
Abstract Number: 1885 • ACR Convergence 2025
Sex-specific Associations of Anthropometrics, Smoking and Eduction with the Risk of Rheumatoid Athritis: A Nested Case-Control Study
Carl Turesson¹, Linnea arvidsson², Emil Rydell¹ and Ulf Bergström³, ¹Lund University, Malmö, Sweden, ²Lund University, Malmö, ³Lund University, Malmö, Sweden
Background/Purpose: Smoking is an established risk factor for rheumatoid arthritis (RA), and there is also evidence for an association with socioeconomic factors. As RA is…
Abstract Number: 1561 • ACR Convergence 2025
Usefulness of HRCT in screening of interstitial lung disease in patients with systemic sclerosis without risk factors of clinical suspicion
Carlos de la Puente-Bujidos¹, Antia Garcia Fernandez², Verónica García García¹, Jesús Loarce³ and Sandra Garrote-Corral¹, ¹Ramón y Cajal University Hospital, Madrid, Spain, ²Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ³Ramón y Cajal University Hospital, Madrid, Spain
Background/Purpose: In 2019 a European expert consensus suggested that all patients with systemic sclerosis (SSc) should be screened with HRCT for interstitial lung disease (ILD)…
Abstract Number: 0682 • ACR Convergence 2025
Predictors of Severe Outcomes in Scleroderma Renal Crisis: Updated Results from a Single Center Study
Alex Luta¹, Saloni Mitchell² and Virginia Steen³, ¹Hospital for Special Surgery, New York, NY, ²Mount Sinai West and Morningside, New York, NY, ³Georgetown University School of Medicine, Washington, DC
Background/Purpose: Scleroderma Renal Crisis (SRC) is a severe manifestation of Systemic Sclerosis (SSc) associated with elevated morbidity and mortality. We aimed to address the challenges…
Abstract Number: 0437 • ACR Convergence 2025
Lipid Screening in Rheumatoid Arthritis: A Retrospective Cohort Study Highlighting Gaps in Cardiovascular Risk Prevention
Anokhi Saklecha¹, Amelia Khoo², Sierra Mendelsohn², Abhijeet Danve³, Mei Xue Dong⁴ and Lisa Suter², ¹Yale University, New Haven, CT, ²Yale School of Medicine, New Haven, CT, ³Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT, ⁴Yale-New Haven Medical Center, new haven, CT
Background/Purpose: Rheumatoid arthritis (RA) is associated with a 1.5 to 2 fold increased risk of cardiovascular disease (CVD) due to systemic inflammation and endothelial dysfunction.…
Abstract Number: 2658 • ACR Convergence 2025
Risk of Immune-Mediated Inflammatory Diseases and Other Safety Outcomes in Patients with T2DM and Obesity Initiating GLP-1 RA: A Propensity Score-Matched Multi-center Study using the TriNetX Global Network
Hsin-Hua Chen and Wen-Cheng Chao, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes mellitus (T2DM) and obesity due to their beneficial metabolic effects. However,…
Abstract Number: 1884 • ACR Convergence 2025
The Importance of Adherence to Dietary Recommendations for Rheumatoid Arthritis Risk May Be Greater in Younger Individuals – Results from a Nested Case-Control Study
Rebecka Bäcklund¹, Ulf Bergström¹, Michele Compagno¹, Linnea arvidsson², Emil Rydell³, Emily Sonestedt¹ and Carl Turesson³, ¹Lund University, Malmö, Sweden, ²Lund University, Malmö, ³Lund University, Malmö, Sweden
Background/Purpose: Healthy eating habits might prevent the development of rheumatoid arthritis (RA). The impact of such lifestyle factors on the risk of RA may differ…
Abstract Number: 1478 • ACR Convergence 2025
Construction and Validation of a Prediction Model of Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus
Bin Zhou¹, QIn Huang², Pan Wang³ and Qiguo Cui⁴, ¹Nanfang Hospital, Guangzhou, Guangdong, China (People's Republic), ²Nanfang Hospital, Guangzhou, China (People's Republic), ³southern medical university Nanfang Hospital, Guangzhou, China (People's Republic), ⁴Southern Medical Univercity Nanfang Hospital, guang zhou, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs. Cognitive dysfunction (CD) is a common but often underestimated complication in…
Abstract Number: 0677 • ACR Convergence 2025
Increased incidence of sudden cardiac death in systemic sclerosis: estimate & correlates.
Jessica Fairley¹, Elizabeth Paratz², Dylan Hansen³, Susanna Proudman⁴, Joanne Sahhar⁵, Gene-Siew Ngian⁶, Diane Apostolopoulos⁶, Jennifer Walker⁷, Lauren Host⁸, Wendy Stevens¹, Andre La Gerche², Mandana Nikpour⁹ and Laura Ross¹, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia, ³St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia, ⁴The University of Adelaide, Adelaide, Victoria, Australia, ⁵Monash Health, Melbourne, Victoria, Australia, ⁶Monash University, Melbourne, Victoria, Australia, ⁷Flinders University, Adelaide, Victoria, Australia, ⁸Fiona Stanley Hospital, Perth, Victoria, Australia, ⁹University of Sydney, School of Public Health, Faculty of Medicine and Health, Sydney, New South Wales, Australia; St Vincent’s Hospital Melbourne, Department of Rheumatology, Fitzroy, Victoria, Australia, Melbourne, Victoria, Australia
Background/Purpose: The incidence of sudden cardiac death (SCD) is suspected to be increased in systemic sclerosis (SSc). However, data describing SCD incidence in SSc are…
Abstract Number: 0436 • ACR Convergence 2025
Why Do Patients with Rheumatic Disease Have MACE and Thrombotic Events?
Andrea Mazariego and Maria Greenwald, Desert Medical Advances, Rancho Mirage, CA
Background/Purpose: Patients with rheumatic disease have an increased risk for thrombotic events and major adverse cardiac events (MACE) due to systemic inflammation. Bleeding time is…
Abstract Number: 2630 • ACR Convergence 2025
The Absence of DORIS Remission Is Associated with Greater Risk of Preterm Birth and Preeclampsia in SLE Pregnancies
Camila Hernández-Blanco¹, Philip Carlucci², Peter Izmirly³, Jessica Dai⁴, Mala Masson⁵, Michael Belmont¹, Amit Saxena⁶, Jane Salmon⁷, Justin Brandt¹ and Jill Buyon⁸, ¹NYU Langone Health, New York, NY, ²New York University School of Medicine, New York, NY, ³New York University Grossman School of Medicine, New York, NY, ⁴New York University Grossman School of Medicine, Tenafly, NJ, ⁵NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁶Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁷Hospital for Special Surgery, New York, NY, ⁸NYU Grossman School of Medicine, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) primarily affects females of childbearing age and increases the risk of adverse pregnancy outcomes (APOs), particularly in non-White individuals and…

1
2
3
…
28
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].